Pilot study to test a digital health program for the blended therapy of unipolar depression and anxiety disorder in adults

Submission date	Recruitment status	[X] Prospectively registered		
25/01/2022	No longer recruiting	[X] Protocol		
Registration date	Overall study status	Statistical analysis plan		
26/01/2022	Completed	Results		
Last Edited	Condition category	Individual participant data		
10/08/2023	Mental and Behavioural Disorders	Record updated in last year		

Plain English summary of protocol

Background and study aims

Over the past decade, there has been a growing interest in internet-delivered cognitive behavioral therapy (iCBT) solutions for the treatment of cognitive and psychological disorders. These programs consist of digital interventions based on cognitive behavioral therapy (CBT) that are usually delivered via the internet through a smartphone or computer. Internet-delivered CBT programs provide several advantages, for example, they can be readily accessed when needed and they can drastically increase the functional capacity of the healthcare system. The aim of this study, which is the pilot of ISRCTN11129335 (https://www.isrctn.com/ISRCTN11129335), is to test a digital health program for the combined treatment of unipolar depression and anxiety disorder in adults.

Who can participate?

Patients aged 18 to 65 years old with depression or anxiety disorders receiving cognitive behavioral therapy (CBT) in outpatient clinics

What does the study involve?

Participants will get access to a digital health application (Elona) in addition to their outpatient psychotherapy aiming to support and amplify the therapeutic process. This group of patients will be compared to another group of patients that receives conventional cognitive behavioral therapy and access to the app after their participation in the study. All patients will fill out an online questionnaire at the beginning, middle (after 6 weeks) and end of the 12-week period of their participation. The study will take place in outpatient clinics, including the university outpatient clinic of the HHU Düsseldorf as the main research center.

What are the possible benefits and risks of participating?

Participants could benefit from a better and/or faster recovery in their symptoms, while the negative effects of the smartphone program are relatively small due to the constant weekly face-to-face therapy sessions. It is expected that patients receiving both CBT and the support of the digital health application will report fewer symptoms and/or greater improvement in other areas of their personal life than patients receiving CBT without additional support. As all

patients will be receiving CBT, which is a validated and efficient psychotherapeutic approach, the risks of the intervention are low.

Where is the study run from? Heinrich-Heine-Universität Düsseldorf (Germany)

When is the study starting and how long is it expected to run for? April 2021 to September 2022

Who is funding the study?

- 1. Heinrich-Heine-Universität Düsseldorf (Germany)
- 2. Elona Health GmbH (Germany)

Who is the main contact? Jan Kalde jan.kalde@hhu.de

Contact information

Type(s)

Scientific

Contact name

Mr Jan Kalde

ORCID ID

http://orcid.org/0000-0003-1880-1861

Contact details

Heinrich-Heine-Universität Düsseldorf Klinische Psychologie Universitätsstraße 1 Duesseldorf Germany 40225 +49 (0)211 81 12140 jan.kalde@hhu.de

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

EL-P01DEP

Study information

Scientific Title

Pilot study to evaluate a digital health application for the blended treatment of unipolar depression and anxiety disorder in adults

Study objectives

Primary hypotheses:

P1: Patients receiving blended cognitive-behavioural therapy (bCBT) with Elona experience stronger improvements in depression symptoms (assessed with the BDI-II) compared to patients receiving treatment as usual (TAU) after 6 and 12 weeks of treatment.

P2: Patients receiving bCBT with Elona experience stronger improvements in anxiety symptoms (assessed with the BAI) compared to patients receiving TAU after 6 and 12 weeks of treatment.

Secondary hypotheses:

S1: Patients receiving bCBT with Elona experience stronger improvements in depression symptoms (assessed with the PHQ-9) compared to patients receiving TAU after 12 weeks of treatment.

S2: Patients receiving bCBT with Elona experience stronger improvements in anxiety symptoms (assessed with the GAD-7) compared to patients receiving TAU after 12 weeks of treatment. S3: Patients receiving bCBT with Elona experience stronger improvements in their quality of life (assessed with the WHOQOL- BREF) compared to patients receiving TAU after 12 weeks of treatment.

S4: Patients receiving bCBT with Elona experience stronger improvements in their work and social adjustment (assessed with the WSAS) compared to patients receiving TAU after 12 weeks of treatment.

S5: Patients receiving bCBT with Elona experience stronger improvements in their self-efficacy (assessed with the SWE) compared to patients receiving TAU after 6/12 weeks of treatment. S6: Patients receiving bCBT with Elona experience stronger improvements in their mental health literacy (assessed with the MHLS) compared to patients receiving TAU after 6/12 weeks of treatment.

S7: Patients receiving bCBT with Elona show higher adherence (assessed through self- and psychotherapist-report) compared to patients receiving TAU after 6/12 weeks of treatment. S8: Patients receiving bCBT with Elona report fewer therapy-related negative events compared to patients receiving TAU after 6/12 weeks of treatment.

S9: Patients receiving bCBT with Elona show a stronger working alliance (assessed through self-and psychotherapist-report) compared to patients receiving TAU after 6/12 weeks of treatment.

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 25/01/2022, Heinrich-Heine-University Duesseldorf Ethics Committee (Moorenstrasse 5, Dusseldorf, 40225, Germany; +49 (0)211 81-19591; Ethikkommission@med.uni-duesseldorf. de), ref: 2021-1470 1

Study design

Multi-centre randomized single-blind controlled study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

GP practice

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use contact details to request a participant information sheet

Health condition(s) or problem(s) studied

Unipolar depression and anxiety disorders

Interventions

Elona is a digital health application that supports patients in outpatient psychotherapy in the treatment of mental illnesses (depression, anxiety/panic disorders, hypochondriacal disorders) through an intelligent delivery of therapeutic content between regular therapy sessions. With Elona, psychotherapists can assign interventions, helpful activities, exercises and psychoeducational resources that provide patients with information and treatment techniques related to their mental illness. Thus, 400 different types of interventions, techniques, exercises, and psychoeducation based on CBT are available beyond the regular therapy session through the Elona smartphone application. The content is based on current and evidence-based therapeutic methods in cognitive behavioral therapy (CBT). By using psychometric questionnaires and exercises, Elona individualizes the content to the needs of the patient. The application is designed to strengthen the active cooperation and participation of patients in outpatient psychotherapy and to integrate therapeutic contents into the daily life of the patient.

To test the effectiveness and safety of Elona an RCT for patients with a clinical diagnosis of depression (including ICD-10: F32.x, F33.x, F34.x) or anxiety disorder (including ICD-10: F40.x, F41.x) based on ICD-10 criteria is planned. The RCT comprises two arms: Participants assigned to the treatment group will get access to the Elona device. The other group will get access to Elona after 12 weeks. All groups will have full access to TAU (weekly face-to-face psychotherapeutic treatment in CBT) over a 12-week period. For the primary and secondary objectives, for each patient group (depression and anxiety) a 2x3 intention-to-treat analyses (pre vs. mid vs. post) design will be used.

Participants assigned to the treatment group are able to work with those as an add-on to TAU.

After agreeing to the informed consent, randomization will take place during enrolment in the electronic data capture system (EDC) via the therapists in an online randomization tool.

Assessments will take place at baseline (T0), mid 6-week treatment (T1) and 12-week after treatment start (T2) as a self-report. Patients' self-report data are collected, including basic demographic questions via the EDC. The questionnaire includes the German version of the Beck Depression Inventory Version 2 (BDI II) (Kühner et al., 2007), the Beck Anxiety Inventory (BAI) (Margraf & Ehlers, 2007), the Penn State Worry Questionnaire (PSWQ) (Glöckner-Rist & Rist, 2006), the Patient Health Questionnaire (PHQ-9) (Spitzer et al., 1999), German Version: PHQ-9

(Löwe et al., 2004), the Generalized Anxiety Disorder 7 (GAD-7) (Löwe et al., 2015) and the brief version of the quality of life scale by the World Health Organization (WHOQOL- BREF) (Angermeyer et al., 2002) to assess medical benefits. Additionally, patients will provide data on patient-relevant and structural improvements measures such as the Work and Social Adjustment Scale (WSAS) (Mundt et al., 2002), German version: ASAS (Heissel et al., 2021), a self-efficacy scale (SWE) (Jerusalem & Schwarzer, 2003), the Negative Effects Questionnaire (NEQ) (Rozental et al., 2019), Working Alliance Inventory - Kurzform (WAI-SR) (Wilmers et al., 2008) and the Mental Health Literacy Scale (MHLS) (O'Connor & Casey, 2015).

Also, patients will further receive four non-standardized 5-point Likert scale items to measure therapy adherence.

Psychotherapists will also provide an objective third-party report on the WAI-SR and patients' therapy adherence.

Intervention Type

Behavioural

Primary outcome measure

Group 1 (patients with depression):

Depression symptoms measured using the 5-point (Likert Scale) BDI-II online questionnaire at the beginning of the treatment and after 6 and 12 weeks

Group 2 (patients with anxiety):

Anxiety symptoms measured using the 5-point (Likert Scale) BAI online questionnaire at the beginning of the treatment and after 6 and 12 weeks

Secondary outcome measures

Groups 1 and 2:

- 1. Quality of life measured using the 5-point (Likert Scale) WHOQOL- BREF online questionnaire at the beginning of the treatment and after 6 and 12 weeks
- 2. Work and social adjustment measured using the 9-point (Likert scale) WSAS (ger.: ASAS) online questionnaire at the beginning of the treatment and after 6 and 12 weeks
- 3. Self-efficacy measured using the 4-point (Likert scale) SWE online questionnaire at the beginning of the treatment and after 6 and 12 weeks
- 4. Negative effects measured using the 5-point (Likert scale) NEQ online questionnaire at the beginning of the treatment and after 6 and 12 weeks
- 5. Working alliance measured using the 5-point (Likert scale) WAI-SR online questionnaire at the beginning of the treatment and after 6 and 12 weeks
- 6. Mental health literacy measured using the 5-point (Likert scale) MHLS online questionnaire at the beginning of the treatment and after 6 and 12 weeks
- 7. Willingness to comply with homework or interventions, measured using non-standardized items 5-point (Likert Scale) online questionnaire at the beginning of the treatment and after 6 and 12 weeks

Overall study start date

22/04/2021

Completion date

01/09/2022

Eligibility

Key inclusion criteria

- 1. All participants must have been diagnosed with one of the following ICD-10 diagnoses:
- F32: Depressive episode
- F32.0: Mild depressive episode
- F32.1: Moderate depressive episode
- F32.2: Severe depressive episode without psychotic symptoms
- F32.8: Other depressive episodes
- F32.9: Depressive episode, unspecified
- F33: Recurrent depressive disorder
- F33.0: Recurrent depressive disorder, current episode mild
- F33.1: Recurrent depressive disorder, current episode moderate
- F33.2: Recurrent depressive disorder, current episode severe without psychotic symptoms
- F33.8: Other recurrent depressive disorders
- F33.9: Recurrent depressive disorder, unspecified
- F34: Persistent mood [affective] disorders
- F34.0: Cyclothymia
- F34.1: Dysthymia
- F34.8: Other persistent mood [affective] disorders
- F34.9: Persistent mood [affective] disorder, unspecified
- F40.0 Agoraphobia
- F40.00 Agoraphobia without panic disorder
- F40.01 Agoraphobia with panic disorder
- F40.1 Social phobias
- F40.2 Specific (isolated) phobias
- F40.8 Other phobic anxiety disorders
- F40.9 Phobic anxiety disorder, unspecified
- F41.0 Panic disorder [episodic paroxysmal anxiety]
- F41.1 Generalized anxiety disorder
- F41.2 Mixed anxiety and depressive disorder
- F41.3 Other mixed anxiety disorders
- F41.8 Other specified anxiety disorders
- F41.9 Anxiety disorder, unspecified

F45.2 Hypochondriacal disorder

- 2. Participants need to be between the age of 18 and 65 years
- 3. Participants need to possess sufficient German language skills (in writing and reading)
- 4. Participants need to possess a smartphone (iOS or Android operating system) with internet access
- 5. Participants need to provide signed and dated informed consent and are willing to comply with the protocol

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Upper age limit

65 Years

Sex

Both

Target number of participants

200

Key exclusion criteria

- 1. All participants without the inclusion ICD-10 diagnosis criteria as well as participants with the following ICD-10 diagnoses are excluded:
- 1.1. F0x.x: Organic, including symptomatic, mental disorders
- 1.2. F1x.x Mental and behavioural disorders due to psychoactive substance use (except F17.x)
- 1.3. F2x.x: Schizophrenia, schizotypal and delusional disorders
- 1.4. F31: Bipolar affective disorder
- 1.5. F32.3: Severe depressive episode with psychotic symptoms
- 1.6. F33.3: Recurrent depressive disorder, current episode severe with psychotic symptoms
- 2. Individuals with acute suicidality (operationalized via BDI-II screening question greater than 1 or first checkup) are excluded from this study first checkup)
- 3. Participants under the age of 18 years
- 4. Participants without any access to a smartphone (iOS or Android operating system) with internet access
- 5. Participants without German language proficiency

If a participant is currently enrolled or is planning to participate in a potentially confounding drug or device trial during the study, enrollment into this study needs to be pre-approved

Date of first enrolment

27/01/2022

Date of final enrolment

30/04/2022

Locations

Countries of recruitment

Germany

Study participating centre

Psychotherapeutische Institutsambulanz der Heinrich-Heine-Universität

Graf-Adolf-Straße 63

Duesseldorf Germany 40210

Study participating centre
Praxis am Volksgarten Dr. Peter Neudeck
Volksgartenstraße 36
Cologne
Germany
50677

Study participating centre
Psychotherapeutische Praxis Jan Kalde
Mauritiussteinweg 98
Cologne
Germany
50676

Study participating centre
AVT Institutsambulanz Barbarossaplatz
Barbarossaplatz 2
Cologne
Germany
50674

Study participating centre AVT GmbH Akademie für Verhaltenstherapie Venloer Str 47-53 Cologne Germany 50672

Sponsor information

Organisation

Heinrich Heine University Düsseldorf

Sponsor details

Universitätsstr. 1 Duesseldorf Germany 40225 +49 (0) 211 81 11 R.Pietrowsky@uni-duesseldorf.de

Sponsor type

University/education

Website

http://www.uni-duesseldorf.de/home/en/home.html

ROR

https://ror.org/024z2rq82

Funder(s)

Funder type

University/education

Funder Name

Heinrich-Heine-Universität Düsseldorf

Alternative Name(s)

Heinrich Heine University Düsseldorf, HHU

Funding Body Type

Government organisation

Funding Body Subtype

Local government

Location

Germany

Funder Name

Elona Health GmbH

Results and Publications

Publication and dissemination plan

The results are planned to be published in a peer-review academic journal after the end of the trial.

Intention to publish date

01/09/2022

Individual participant data (IPD) sharing plan

Participant level data (anonymised data) is available upon request from Jan Kalde (jan. kalde@hhu.de), there is participant consent for 10 years for other research institutions, but only including bCBT studies in Germany.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol file	version 2.2		26/01/2022	No	No